Top

Published in:

01-06-2009 | SHORT REPORT

Rhinitis and epistaxis in patients treated by anti-angiogenic therapy

Authors: V. Prulière-Escabasse, E. Escudier, R. Balheda, J. C. Soria, A. Coste, C. Massard

Published in: Investigational New Drugs | Issue 3/2009

Summary

Anti-angiogenic therapies have a particular drug-related toxicity profile including hypertension, thrombosis, haemorrhages, and proteinuria. Moreover, patients treated by angiogenesis inhibitors present nasal symptoms including symptomatic rhinitis and epistaxis. For the first time, a new entity of “atrophic rhinitis” induced by angiogenesis inhibitors is described and revealed that angiogenesis inhibitors alter the differentiation of nasal epithelium. VEGF may act on epithelial cell proliferation and differentiation in nasal epithelium.

Ferrara N, Kerbel RS (2005) Angiogenesis as a therapeutic target. Nature 438(7070):967–974 doi:10.1038/nature04483 CrossRefPubMed

Kerbel RS (2008) Tumor angiogenesis. N Engl J Med 358(19):2039–2049 doi:10.1056/NEJMra0706596 CrossRefPubMed

Lalej-Bennis D, Boillot J, Bardin C, Zirinis P, Coste A, Escudier E et al (2001) Efficacy and tolerance of intranasal insulin administered during 4 months in severely hyperglycaemic type 2 diabetic patients with oral drug failure: a cross-over study. Diabet Med 18(8):614–618 doi:10.1046/j.1464-5491.2001.00528.x CrossRefPubMed

Coste A, Brugel L, Maître B, Boussat S, Papon JF, Wingerstmann L et al (2000) Inflammatory cells as well as epithelial cells in nasal polyps express vascular endothelial growth factor. Eur Respir J 15(2):367–372 doi:10.1034/j.1399-3003.2000.15b24.x CrossRefPubMed

Brown KRS, England KM, Goss KL, Snyder JM, Acarregui MJ (2001) VEGF induces airway epithelial cell differentiation in human fetal lung in vitro. Am J Physiol Lung Cell Mol Physiol 281:1001–1010

Title: Rhinitis and epistaxis in patients treated by anti-angiogenic therapy
Authors: V. Prulière-Escabasse
E. Escudier
R. Balheda
J. C. Soria
A. Coste
C. Massard
Publication date: 01-06-2009
Publisher: Springer US
Published in: Investigational New Drugs / Issue 3/2009
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI: https://doi.org/10.1007/s10637-008-9168-6

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Summary

Please log in to get access to this content

Other articles of this Issue 3/2009

N-benzoxazol-2-yl-N′-1-(isoquinolin-3-yl-ethylidene)-hydrazine, a novel compound with antitumor activity, induces radicals and dissipation of mitochondrial membrane potential

Antiviral activity of cidofovir against telomerase-specific replication-selective oncolytic adenovirus, OBP-301 (Telomelysin)

Antioxidant and anticancer efficacy of hesperidin in benzo(a)pyrene induced lung carcinogenesis in mice

Open-label phase I trial of vandetanib in combination with mFOLFOX6 in patients with advanced colorectal cancer

A phase II trial of chemoradiation therapy with weekly oxaliplatin and protracted infusion of 5-fluorouracil for esophageal cancer

Phase I trial of neoadjuvant chemoradiotherapy (CRT) with capecitabine and weekly irinotecan followed by laparoscopic total mesorectal excision (LTME) in rectal cancer patients

Keynote webinar | Spotlight on antibody–drug conjugates in cancer